Literature DB >> 21235406

Observation of pain control in patients with bisphosphonate-induced osteonecrosis using low level laser therapy: preliminary results.

Umberto Romeo1, Alexandros Galanakis, Christos Marias, Alessandro Del Vecchio, Gianluca Tenore, Gaspare Palaia, Paolo Vescovi, Antonella Polimeni.   

Abstract

BACKGROUND: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is an adverse side effect associated with bisphosphonate (BP) therapy, especially when parenteral BP administration is used. Patients affected by BRONJ present wide areas of exposed necrotic bone, particularly after surgical oral procedures. The main symptom is pain that is poorly controlled by common analgesic drugs. Recently, many studies have pointed to the beneficial effect of low-level laser therapy (LLLT) in pain reduction for many pathological conditions. The purpose of this study is to investigate whether LLLT could be helpful in managing BRONJ by reducing the problems associated with this condition and the use of analgesic drugs.
METHODS: Twelve patients affected by BRONJ were monitored at the Complex Operative Unit of Oral Pathology. Among these patients, only seven referred to pain in necrotic areas and were recruited for LLLT. Laser applications were performed with a double diode laser simultaneously emitting at two different wavelengths (λ = 650 nm and λ = 904-910 nm, spot size = 8 mm). All of the patients were irradiated with a fluence of 0.053 J/cm(2) for 15 min five times over a period of 2 weeks, in a non-contact mode, ∼1 mm from the pathologic area. The patient's maximum and minimum pain was recorded using a numeric rating scale (NRS) evaluation before and after the treatment. Statistical analysis was performed using the Kruskal-Wallis test.
RESULTS: Six patients showed significant pain reduction, and only one patient indicated a worsening of the symptoms, which was probably related to a reinfection of the BRONJ site, which occurred during the study. A statistically significant difference (p < 0.05) was found between the NRS rates before and after the protocol.
CONCLUSIONS: This pilot study suggests that LLLT may be a valid technique to support the treatment of BRONJ-related pain, even though the low number of cases in this study does not permit any conclusive consideration.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21235406     DOI: 10.1089/pho.2010.2835

Source DB:  PubMed          Journal:  Photomed Laser Surg        ISSN: 1549-5418            Impact factor:   2.796


  22 in total

1.  High-frequency low-level diode laser irradiation promotes proliferation and migration of primary cultured human gingival epithelial cells.

Authors:  Kenichiro Ejiri; Akira Aoki; Yoko Yamaguchi; Mitsuhiro Ohshima; Yuichi Izumi
Journal:  Lasers Med Sci       Date:  2013-03-21       Impact factor: 3.161

2.  Photobiomodulation therapy: management of mucosal necrosis of the oropharynx in previously treated head and neck cancer patients.

Authors:  Joel B Epstein; Paul Y Song; Allen S Ho; Babak Larian; Arash Asher; Rene-Jean Bensadoun
Journal:  Support Care Cancer       Date:  2016-12-17       Impact factor: 3.603

3.  Continuous Mandibular Nerve Block for Intractable Mandibular Pain Due to Antiresorptive Agent-Related Osteonecrosis of the Jaw: A Case Report.

Authors:  Daichi Fujimoto; Norihiko Obata; Yasushi Motoyama; Hitoaki Sato; Yumiko Takao; Satoshi Mizobuchi
Journal:  Kobe J Med Sci       Date:  2020-11-17

Review 4.  Low-level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 2: proposed applications and treatment protocols.

Authors:  Judith A E M Zecha; Judith E Raber-Durlacher; Raj G Nair; Joel B Epstein; Sharon Elad; Michael R Hamblin; Andrei Barasch; Cesar A Migliorati; Dan M J Milstein; Marie-Thérèse Genot; Liset Lansaat; Ron van der Brink; Josep Arnabat-Dominguez; Lisette van der Molen; Irene Jacobi; Judi van Diessen; Jan de Lange; Ludi E Smeele; Mark M Schubert; René-Jean Bensadoun
Journal:  Support Care Cancer       Date:  2016-03-17       Impact factor: 3.603

Review 5.  The use of low-level light therapy in supportive care for patients with breast cancer: review of the literature.

Authors:  Jolien Robijns; Sandrine Censabella; Paul Bulens; Annelies Maes; Jeroen Mebis
Journal:  Lasers Med Sci       Date:  2016-08-19       Impact factor: 3.161

6.  The effect of laser therapy on the expression of osteocalcin and osteopontin after tooth extraction in rats treated with zoledronate and dexamethasone.

Authors:  Giovanni Mergoni; Paolo Vescovi; Roberto Sala; Elisabetta Merigo; Pietro Passerini; Roberta Maestri; Domenico Corradi; Paolo Govoni; Samir Nammour; Massimiliano G Bianchi
Journal:  Support Care Cancer       Date:  2015-07-21       Impact factor: 3.603

7.  Low-level laser therapy for osteonecrotic lesions: effects on osteoblasts treated with zoledronic acid.

Authors:  Fernanda Gonçalves Basso; Ana Paula Silveira Turrioni; Diana Gabiela Soares; Vanderlei Salvador Bagnato; Josimeri Hebling; Carlos Alberto de Souza Costa
Journal:  Support Care Cancer       Date:  2014-05-07       Impact factor: 3.603

8.  The Effectiveness of the Low-Level Laser, Antibiotic and Surgical Therapy in the Treatment of Medication-Related Osteonecrosis of the Jaws: A Case Report.

Authors:  Maria Del Pilar Rodríguez-Sánchez; Cristian Statkievicz; João Martins de Mello-Neto; Luan Felipe Toro; Ana Paula Farnezzi Bassi; Valdir Gouveia Garcia; Letícia Helena Theodoro; Edilson Ervolino
Journal:  J Lasers Med Sci       Date:  2020-01-18

Review 9.  Bisphosphonate-related osteonecrosis of the jaw: a review of the potential efficacy of low-level laser therapy.

Authors:  S Latifyan; M T Genot; J Klastersky
Journal:  Support Care Cancer       Date:  2016-03-31       Impact factor: 3.603

Review 10.  Efficacy of laser therapy in the management of bisphosphonate-related osteonecrosis of the jaw (BRONJ): a systematic review.

Authors:  João Batista Blessmann Weber; Renata Stifelman Camilotti; Monique Estér Ponte
Journal:  Lasers Med Sci       Date:  2016-03-30       Impact factor: 3.161

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.